Related Experiment Videos
Immunoprophylaxis and the control of respiratory syncytial virus disease
1Department of Pediatrics, New England Medical Center, Boston, MA 02111, USA.
Pediatrics
|August 1, 1997
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Safety of palivizumab in preterm infants 29 to 32 weeks' gestational age without chronic lung disease to prevent serious respiratory syncytial virus infection.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2003
Respiratory syncytial virus prophylaxis--the story so far.
Respiratory medicine·2002
Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial. Northern Hemisphere Expanded Access Study Group.
The Pediatric infectious disease journal·2001
Meningococcal disease among children who live in a large metropolitan area, 1981-1996.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2001
Respiratory syncytial virus immunoprophylaxis: impact on epidemiology.
Paediatric drugs·2000
Hereditary TTP and Hemolytic Anemia in Newborns.
Pediatrics·2026